Ipca Laboratories, after resolving regulatory hurdles and integrating Unichem, is set to re-enter the US generics market aiming for $200 million in revenue within 12-18 months. The focus is on commercializing existing products after an import ban by the US FDA was lifted. Unichem has shown profits following these efforts.
